Entering text into the input field will update the search result below

Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q4 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET

Company Participants

Juan Sanchez – Vice President-Corporate Communications and Investor Relations

Sharon Mates – Chairman and Chief Executive Officer

Mark Neumann – Executive Vice President and Chief Commercial Officer

Larry Hineline – Senior Vice President and Chief Financial Officer

Conference Call Participants

Jessica Fye – JPMorgan

Brian Abrahams – RBC Capital Markets

Andrew Tsai – Jefferies

Mike DiFiore – Evercore ISI

Charles Duncan – Cantor Fitzgerald

Rudy Li – SVB Leerink

Jason Gerberry – Bank of America

Ami Fadia – Needham


Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies Fourth Quarter and Year-End Financial Results Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] As a reminder, today’s conference call is being recorded.

I’d now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Sanchez

Good morning and thank you all for joining us today. Our earnings press release provides our corporate update and details of the company’s financial results for the fourth quarter and year ended December 31, 2021. This press release crossed the wire a short time ago and is available on our website.

Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Executive Vice President and Chief Commercial Officer; and Larry Hineline, Senior Vice President and Chief Financial Officer.

As a reminder, during today’s call, we will be making certain forward-looking statements. These statements may include statements regarding among other things, the efficacy, safety, and intended use of the company’s product development candidates, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and results of ongoing and future clinical trials, plans regarding regulatory filings, future research and development, our

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.